Edwards Lifesciences Corp (NYSE:EW) climbed 11 percent after the company won a court ruling that limited the sale of Medtronic’s (MDT) CoreValve system in the US. Edwards Lifesciences Corp (NYSE:EW) stock performance was 11.00% in last session and finished the day at $81.00. Traded volume was 7.23million shares in the last session and the average volume of the stock remained 1.36million shares. The beta of the stock remained 0.47. Edwards Lifesciences Corp (NYSE:EW) insider ownership is 0.50%.

Jefferies downgraded the stock to “hold” from “buy,” a session after Johnson & Johnson said it won’t develop an anti-wrinkle cream to rival Allergan, Inc.’s (NYSE:AGN) Botox. Allergan, Inc. (NYSE:AGN) rose 2.55 percent to $123.97 Monday on volume of 7.18million shares. The intra-day range of the stock was $120.72 to $124.46. Allergan, Inc. (NYSE:AGN) has a market capitalization of $37.08billion.

Akebia Therapeutics Inc (NASDAQ:AKBA), a biopharmaceutical company, was initiated with a Buy rating and a price target of $28.00 per share by brokerage firm UBS. Akebia Therapeutics Inc (NASDAQ:AKBA)’s stock on Apr 14, 2014 reported a increase of 25.39% to the closing price of $21.14. Its fifty two weeks range is $16.41 -$28.50. The total market capitalization recorded $409.76million. The overall volume in the last trading session was 3.07million shares. In its share capital, AKBA has 20.26million outstanding shares.

Acorda Therapeutics Inc (NASDAQ:ACOR) Shares get upgraded to Outperform from Perform at FBR Capital, which takes its target price to $47 from $30. Plumiaz, to treat epilepsy seizures, offers promise, the bank believes. On Monday, shares of Acorda Therapeutics Inc (NASDAQ:ACOR) advanced 1.93% to close the day at $35.87. Company return on investment (ROI) is 4.00% and its monthly performance is recorded as -3.81%. Acorda Therapeutics Inc (NASDAQ:ACOR) quarterly revenue growth is 20.49%.